Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Ursodiol. Always confirm against the full prescribing information.
100 interactions
Acetylsalicylic acid
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ursodeoxycholic acid.
Level 1 evidence
Aluminium phosphate
Aluminium phosphate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Aluminum chloride
Aluminum chloride can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Aluminum chlorohydrate
Aluminum chlorohydrate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Aluminum hydroxide
Aluminum hydroxide can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Aluminum sulfate
Aluminum sulfate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Level 1 evidence
Anagrelide
The risk or severity of adverse effects can be increased when Anagrelide is combined with Ursodeoxycholic acid.
Level 1 evidence
Atazanavir
Ursodeoxycholic acid may decrease the excretion rate of Atazanavir which could result in a higher serum level.
Level 2 evidence
Atenolol
Ursodeoxycholic acid may decrease the excretion rate of Atenolol which could result in a higher serum level.
Level 2 evidence
Atorvastatin
Ursodeoxycholic acid may decrease the excretion rate of Atorvastatin which could result in a higher serum level.
Level 2 evidence
Atropine
Ursodeoxycholic acid may decrease the excretion rate of Atropine which could result in a higher serum level.
Level 2 evidence
Belantamab mafodotin
Ursodeoxycholic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Ursodiol has 152 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Ursodiol has 1 major, 105 moderate, and 46 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Ursodiol. Always confirm against the full prescribing information.